Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.

ABSTRACT: Transplantation is limited by the need for life-long pharmacological immunosuppression, which carries significant morbidity and mortality. Regulatory T cell (Treg) therapy holds significant promise as a strategy to facilitate immunosuppression minimization. Polyclonal Treg therapy has been assessed in a number of Phase I/II clinical trials in both solid organ and hematopoietic transplantation. Attention is now shifting towards the production of alloantigen-reactive Tregs (arTregs) through co-culture with donor antigen. These allospecific cells harbour potent suppressive function and yet their specificity implies a theoretical reduction in off-target effects. This review will cover the progress in the development of arTregs including their potential application for clinical use in transplan

SUBMITTER: Alzhrani A 

PROVIDER: S-EPMC8482792 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature